

Course Syllabus



Accreditation Statement:



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, American Academy of Addiction Psychiatry is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Target Audience Statement

This intensive, 14-hour, online course is designed for physicians and other health care professionals who have a foundation in prescribing medication for patients with substance use disorders, including those with co-occurring psychiatric conditions, but would like a deeper understanding of these pharmacotherapies. Credit for this activity is designated for learners in the following ways:

Physician Designation Statement

American Academy of Addiction Psychiatry designates this Other activity (one portion of this course is an independent online activity and another portion of this course is a live face-to-face educational exchange with a clinical expert responding to learner questions) for a maximum of 14.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Health	Professionals	Designation	Statement
			Participants will receive a Certificate of Attendance stating this program is designated for 14.25 <i>AMA PRA Category 1 Credits™</i> . This credit is accepted by the AANP and the AAPA.

Educational Objectives:

After participating in this course, learners should be able to:

1. Use methadone, buprenorphine and injectable OUD pharmacotherapies in clinical practice for the treatment of opioid use disorders.
2. Evaluate medication treatments for alcohol use disorders.
3. Determine when to use varenicline, bupropion, and nicotine replacement therapy (NRT) for treatment of nicotine use disorders.
4. Review treatment issues related to stimulant use disorder pharmacotherapy.
5. Evaluate new evidence for medication treatments for cannabis use disorder.
6. Discuss new evidence for inpatient and outpatient medications for the treatment of sedative-hypnotic use disorder.
7. List evidence-based options for treating patients using psychedelics to treat substance use disorders.

8. Review evidence-based non-pharmacological treatments such as brain stimulation for treatment of patients with primary and co-occurring substance use disorders.

Faculty:

- Derek Blevins, MD
- Christina A. Brezing, MD
- Elias Dakwar, MD
- Kevin M. Gray, MD
- John J. Mariani, MD
- Larissa Mooney, MD
- Richard Rosenthal, MA, MD
- Kevin A. Sevarino, MD, PhD
- Jill M. Williams, MD

Topics:

- Alcohol Use Disorder Pharmacotherapy
- Brain Stimulation
- Cannabis Use Disorder Pharmacotherapy
- Nicotine Use Disorder Pharmacotherapy
- Opioid Use Disorder Pharmacotherapy
- Psychedelics/Ketamine
- Stimulant Use Disorder Pharmacotherapy
- Sedative-Hypnotic Use Disorder Pharmacotherapy

Schedule:

Saturday, October 21, 2023	
12:00 PM-12:05 PM	<i>Welcome and orientation to the course</i> John Mariani, MD and Kevin Sevarino, MD, PhD
12:05 PM-1:00 PM	Opioid Use Disorder Pharmacotherapy <i>Oral OUD Pharmacotherapy and Pain Management</i> Kevin Sevarino, MD, PhD
1:00 PM-1:55 PM	Opioid Use Disorder Pharmacotherapy <i>Injectable OUD Pharmacotherapy</i> John Mariani, MD
1:55 PM-2:10 PM	Break
2:10 PM-2:45 PM	Alcohol Use Disorder Pharmacotherapy <i>From Detox to Relapse Prevention; Medication Treatments for AUD</i> Richard Rosenthal, MD
2:45 PM-3:00 PM	Break
3:00 PM-3:35 PM	Tobacco Use Disorder Pharmacotherapy <i>An Underused Arsenal: Varenicline, Bupropion, and NRT</i> Jill Williams, MD

Sunday, October 22, 2023	
12:00 PM-12:05 PM	<i>Welcome and orientation to the course</i> John Mariani, MD and Kevin Sevarino, MD, PhD
12:05 PM-12:40 PM	Stimulant Use Disorder Pharmacotherapy <i>Clinical Effects and Treatment Issues</i> John Mariani, MD – Live Q&A Presenter Larissa Mooney, MD – On-Demand Presenter
12:40 PM-12:55 PM	Break
12:55 PM-1:30 PM	Sedative-Hypnotic Use Disorder Pharmacotherapy <i>Inpatient and Outpatient Medication Approaches</i> Christina Brezing, MD
1:30 PM-1:45 PM	Break
1:45 PM-2:20 PM	Cannabis Use Disorder Pharmacotherapy <i>Promising Approaches on the Horizon</i> Kevin Gray, MD
2:20 PM-2:35 PM	Break
2:35 PM-3:10 PM	Brain Stimulation <i>Brain Stimulation for Addiction: Present & Future</i> Derek Blevins, MD
3:10 PM-3:25 PM	Break
3:25 PM-4:00 PM	Ketamine and Psychedelic Treatments for SUD <i>Practical Realities and future directions</i> Elias Dakwar, MD

Disclosure to Learners:

In accordance with the disclosure policy of the American Academy of Addiction Psychiatry, as well as standards set forth by Joint Accreditation for Interprofessional Continuing Education policies and accreditation requirements including the Standards for Integrity and Independence in Accredited Continuing Education, AAAP is expected to present learners with unbiased, independent, and objective information in all of our activities. Therefore, planners, faculty, and all others involved in the planning or content development of this activity must disclose all financial and professional relationships with ineligible companies that have occurred within the past 24 months.

The following faculty has relevant financial relationships with an ineligible company to disclose:

John Mariani, MD	Indivior	Speaker/Consultant
Kevin Gray, MD	Aelis Farma	Research Support
	Jazz Pharmaceuticals	Consultant

All of the relevant financial relationships listed for these individuals have been mitigated. All other planners, faculty, and others in control of the planning and presentation of this activity have no relevant financial relationships with ineligible companies.

All speakers have been advised that any recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in the presentation must conform to the generally accepted standards of experimental design, data collection, and analysis.

Breakdown of Credit:

On-Demand Recorded Lectures		CME Credits
65 Minutes	Use of Oral Medications for Opioid Use Disorder	1.0
75 Minutes	Injectable Medications for the Treatment of Opioid Use Disorder	1.25
60 Minutes	Alcohol Use Disorder Pharmacotherapy	1.0
55 Minutes	Tobacco Use Disorder Pharmacotherapy	1.0
60 Minutes	Stimulant Use Disorder Pharmacotherapy	1.0
60 Minutes	Sedative-Hypnotic Use Disorder Pharmacotherapy	1.0
40 Minutes	Cannabis Use Disorder	.75
55 Minutes	Brain Stimulation	1.0
45 Minutes	Ketamine and Psychedelic Treatments	.75
		8.75
Saturday, October 21, 2023		
12:00 PM	Welcome and Introduction to the Live Session	0.0
12:05 PM-1:00 PM	Opioid Use Disorder Pharmacotherapy <i>Oral OUD Pharmacotherapy and Pain Management</i> Kevin Sevarino, MD, PhD	1.0
1:00 PM-1:55 PM	Opioid Use Disorder Pharmacotherapy <i>Injectable OUD Pharmacotherapy</i> John Mariani, MD	1.0
1:55 PM-2:10 PM	Break	0.0
2:10 PM-2:45 PM	Alcohol Use Disorder Pharmacotherapy <i>From Detox to Relapse Prevention; Medication Treatments for AUD</i> Richard Rosenthal, MD	.5
2:45 PM-3:00 PM	Break	0.0
3:00 PM-3:35 PM	Tobacco Use Disorder Pharmacotherapy <i>An Underused Arsenal: Varenicline, Bupropion, and NRT</i> Jill Williams, MD	.5
3:35-3:45 PM	End of Day Wrap Up	0.0
		3.0

Sunday, October 22, 2023		
12:00 PM	Welcome and Introduction to the Live Session	0.0
12:05 PM-12:40 PM	Stimulant Use Disorder Pharmacotherapy <i>Clinical Effects and Treatment Issues</i> Larissa Mooney, MD	.5
12:40 PM-12:55 PM	Break	0.0
12:55 PM-1:30 PM	Sedative-Hypnotic Use Disorder Pharmacotherapy <i>Inpatient and Outpatient Medication Approaches</i> Christina Brezing, MD	.5
1:30 PM-1:45 PM	Break	0.0
1:45 PM-2:20 PM	Cannabis Use Disorder Pharmacotherapy <i>Promising Approaches on the Horizon</i> Kevin Gray, MD	.5
2:20 PM-2:35 PM	Break	0.0
2:35 PM-3:10 PM	Brain Stimulation <i>Brain Stimulation for Addiction: Present & Future</i> Derek Blevins, MD	.5
3:10 PM-3:25 PM	Break	0
3:25 PM-4:00 PM	Ketamine and Psychedelic Treatments for Substance Use Disorder <i>Practical Realities and Future Directions</i> Elias Dakwar, MD	.5
		2.5

Maximum Credit per Day	CME Credits
On-Demand	8.75
Saturday, October 22, 2023	3.0
Saturday, October 23, 2023	2.5
Grand total 14.25 AMA PRA Category 1 Credits™	